FDA Tightens Raw Data Rules for Food Packaging

On July 15, 2026, a revised FDA guidance for food contact substances moved from notice to immediate compliance significance for suppliers of food packaging to the U.S. market. The update matters because it raises the documentation threshold for PMN and LONO submissions by requiring full original migration testing data, a change that is especially relevant for exporters of plastic packaging, composite films, and biodegradable packaging, as well as the teams managing regulatory filings, testing, customer communication, and delivery schedules.

What the FDA change specifically requires

According to the information provided, the U.S. FDA issued a revised Industry Guidance for Food Contact Substances (FCS) on July 8, 2026. Under this revision, all food packaging suppliers exporting to the United States must, starting July 15, submit complete original migration testing data at the same time when filing a Pre-Market Notification (PMN) or a Letter of Non-Objection (LONO).

The required raw data includes temperature, time, solvent information, and instrument spectra. Based on the provided summary, the updated rule materially increases the technical documentation threshold and is expected to affect certification timelines and compliance costs for Chinese exporters in plastic packaging, composite film, and biodegradable packaging.

Where the pressure is likely to appear across the supply chain

Export-facing packaging manufacturers

From an industry perspective, packaging manufacturers serving the U.S. market are likely to feel the most direct impact because the new requirement attaches to submission materials for PMN and LONO. The likely pressure point is not only testing itself, but whether supporting records are complete enough to withstand review as original data rather than summarized results. What deserves closer attention is the effect on submission readiness and file preparation time.

Testing and regulatory documentation functions

Analysis shows that internal compliance teams and external service providers involved in testing, dossier preparation, and submission management may see a heavier documentation burden. The change points to closer scrutiny of how migration tests are recorded and presented, especially where temperature, duration, solvent conditions, and instrument spectra must be provided together. In practice, this can affect document collection, review workflows, and communication between laboratories and filing teams.

Buyers and project managers handling U.S.-bound orders

Observably, procurement teams, account managers, and project coordinators connected to U.S.-bound packaging business may need to pay more attention to timing risk. The information provided already indicates possible effects on certification cycles and compliance costs. For these roles, the practical concern is whether a product can move through customer approval and regulatory submission without delays caused by incomplete raw data packages.

What companies should monitor now

Whether existing testing files can support immediate submissions

Analysis shows that the first operational question is whether current migration testing records are organized at the raw-data level required by the revised guidance. A test report alone may not address the issue if the submission now needs the underlying temperature, time, solvent, and spectral records at the same time.

How filing timelines may shift in live business

What deserves closer attention is the difference between a rule being effective and a company being ready to execute against it. For exporters with active PMN or LONO work, the key issue is whether additional data collection or file rework could extend internal preparation time and affect customer-facing schedules.

Which product lines face the most immediate documentation pressure

From the information provided, plastic packaging, composite films, and biodegradable packaging are the most clearly exposed categories. Companies active in these segments should focus on whether their U.S.-oriented products already have traceable testing records that can be assembled into a complete submission package without gaps.

How to communicate with customers and service partners

Observably, the new requirement is not only a regulatory matter but also a coordination issue. Suppliers may need closer alignment with laboratories, regulatory service partners, and customers on what documents are required, when they are needed, and how any delay in raw-data assembly could influence delivery commitments or approval expectations.

Why this looks like more than a short-term paperwork update

This section is analysis. It is more appropriate to understand this development as a clear compliance signal rather than a routine administrative adjustment. The requirement to upload complete original migration testing data suggests that documentation depth is becoming more important in market access work for food packaging entering the United States.

At the same time, it would be premature to present this as a fully settled long-term outcome beyond the facts provided. Observably, the immediate confirmed change is the higher filing threshold and the likely effect on certification cycle length and compliance cost. The broader operational impact still needs continued observation in actual submission practice.

How this update is best understood at this stage

At this stage, the FDA revision is best read as an actionable compliance change with immediate business relevance for U.S.-bound food packaging suppliers. The confirmed facts already point to higher documentation demands and possible pressure on timing and cost, especially for Chinese exporters in the named packaging segments. A neutral reading is that this is neither a simple news item nor a basis for exaggerated conclusions; it is a rule change that requires close operational attention and further monitoring as companies move through real filings.

Basis of this article and points still requiring verification

This article is based on the user-provided news title, event date, and event summary. For this type of industry development, source categories commonly worth tracking include official regulatory notices, company disclosures, industry association updates, authoritative media coverage, and standard-setting documents.

No specific official source link was provided in the input, so the exact official link still needs ongoing verification. Follow-up attention should focus on any further FDA wording updates, submission practice details around PMN and LONO, and how the raw-data requirement is reflected in actual certification timelines and compliance workflows.